ST Pharm Co.,Ltd. (237690.KQ)

KRW 79400.0

(0.51%)

Total Liabilities Summary of ST Pharm Co.,Ltd.

ST Pharm Co.,Ltd.'s latest annual total liabilities in 2023 was 299.92 Billion KRW , up 28.52% from previous year.
ST Pharm Co.,Ltd.'s latest quarterly total liabilities in 2024 Q1 was 281.75 Billion KRW , down -6.06% from previous quarter.
ST Pharm Co.,Ltd. reported annual total liabilities of 233.36 Billion KRW in 2022, up 30.91% from previous year.
ST Pharm Co.,Ltd. reported annual total liabilities of 178.25 Billion KRW in 2021, up 16.6% from previous year.
ST Pharm Co.,Ltd. reported quarterly total liabilities of 281.75 Billion KRW for 2024 Q1, down -6.06% from previous quarter.
ST Pharm Co.,Ltd. reported quarterly total liabilities of 211.71 Billion KRW for 2023 Q2, down -9.77% from previous quarter.

Annual Total Liabilities Chart of ST Pharm Co.,Ltd. (2023 - 2015)

Historical Annual Total Liabilities of ST Pharm Co.,Ltd. (2023 - 2015)

Year	Total Liabilities	Total Liabilities Growth
2023	299.92 Billion KRW	28.52%
2022	233.36 Billion KRW	30.91%
2021	178.25 Billion KRW	16.6%
2020	152.87 Billion KRW	287.55%
2019	39.44 Billion KRW	147.3%
2018	15.95 Billion KRW	-51.33%
2017	32.77 Billion KRW	-42.49%
2016	56.98 Billion KRW	-45.75%
2015	105.03 Billion KRW	0.0%

Year	Total Liabilities	Total Liabilities Growth
2024 Q2	235.31 Billion KRW	-16.48%
2024 Q1	281.75 Billion KRW	-6.06%
2023 Q2	211.71 Billion KRW	-9.77%
2023 Q4	299.92 Billion KRW	12.49%
2023 FY	299.92 Billion KRW	28.52%
2023 Q1	234.64 Billion KRW	0.55%
2023 Q3	266.62 Billion KRW	25.94%
2022 Q3	202.3 Billion KRW	-0.52%
2022 FY	233.36 Billion KRW	30.91%
2022 Q4	233.36 Billion KRW	15.35%
2022 Q2	203.36 Billion KRW	8.03%
2022 Q1	188.25 Billion KRW	5.61%
2021 Q4	178.25 Billion KRW	-0.68%
2021 Q1	154.5 Billion KRW	3.82%
2021 Q2	170.08 Billion KRW	10.08%
2021 Q3	179.47 Billion KRW	5.52%
2021 FY	178.25 Billion KRW	16.6%
2020 Q1	39.77 Billion KRW	6.34%
2020 FY	152.87 Billion KRW	287.55%
2020 Q4	148.81 Billion KRW	244.04%
2020 Q3	43.25 Billion KRW	10.76%
2020 Q2	39.05 Billion KRW	-1.81%
2019 Q2	15.63 Billion KRW	-35.54%
2019 Q3	16.93 Billion KRW	8.33%
2019 Q4	37.4 Billion KRW	120.8%
2019 Q1	24.25 Billion KRW	74.04%
2019 FY	39.44 Billion KRW	147.3%
2018 Q1	33.75 Billion KRW	10.96%
2018 FY	15.95 Billion KRW	-51.33%
2018 Q3	9.81 Billion KRW	-47.25%
2018 Q2	18.6 Billion KRW	-44.87%
2018 Q4	13.93 Billion KRW	41.98%
2017 Q2	39.57 Billion KRW	-43.81%
2017 Q1	70.43 Billion KRW	32.47%
2017 Q4	30.42 Billion KRW	-3.75%
2017 FY	32.77 Billion KRW	-42.49%
2017 Q3	31.6 Billion KRW	-20.13%
2016 Q4	53.17 Billion KRW	27.87%
2016 Q2	93.81 Billion KRW	0.0%
2016 Q1	- KRW	-100.0%
2016 Q3	41.58 Billion KRW	-55.68%
2016 FY	56.98 Billion KRW	-45.75%
2015 FY	105.03 Billion KRW	0.0%
2015 Q4	105.03 Billion KRW	0.0%

Peer Total Liabilities Comparison of ST Pharm Co.,Ltd.

Name	Total Liabilities	Total Liabilities Difference
Sam Chun Dang Pharm. Co., Ltd	109.56 Billion KRW	-173.749%
Hyundai Bioscience Co., Ltd.	7.52 Billion KRW	-3887.964%
ABL Bio Inc.	86.06 Billion KRW	-248.485%
Cellid, Co., Ltd.	23.42 Billion KRW	-1180.253%